Novo Nordisk sues Mylan over generic semaglutide ANDA

Novo Nordisk filed suit against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, opening a patent fight over Mylan's abbreviated new drug application (ANDA) for a generic version of semaglutide, the active ingredient in Wegovy.^[1] Novo asserted five patents that are listed, or that Novo intended to list, in the FDA's Orange Book, arguing that Mylan's ANDA filing itself counted as patent infringement under federal law.^[1]

The case, now docketed as Novo Nordisk, Inc. v. Mylan Pharms. Inc., Civ. No. 23-101-CFC, moved through litigation for more than two years before a ruling came down in July 2025.^[1] Mylan asked the court for judgment that it did not infringe one of the five patents, U.S. Patent No. 9,764,003, which covers a method of treatment. Mylan argued that because it is a drug manufacturer, not a treating physician, it cannot directly administer semaglutide to patients and therefore cannot directly infringe a method-of-treatment claim.^[1] Judge Colm Connolly agreed, finding that Novo's complaint did not include specific facts showing Mylan itself would infringe, only a general legal claim that it would.^[1]

The court also entered a stipulated judgment, agreed to by both sides, that Mylan does not contribute to infringement of the same patent.^[1] On a third theory, Novo argued Mylan's product label would induce doctors to infringe by leading them to give semaglutide without any other therapeutic drug, a specific condition in the patent's claims.^[1] The court disagreed. It found Mylan's label tells doctors not to combine the generic with other semaglutide products or other GLP-1 drugs, but does not tell them to leave out other kinds of medicine altogether. In fact, the label tells physicians to consider lowering, not stopping, doses of insulin or insulin-boosting drugs used alongside semaglutide, which the court said undercut Novo's argument.^[1] As a result, the court ruled in Mylan's favor on that patent, rejecting all three infringement theories Novo raised.^[1]

This ruling addressed only one of the five patents Novo originally asserted.^[1] The sources reviewed here do not say what has happened with the other four patents in the case, and it is not yet known when, or whether, a generic semaglutide product from Mylan could reach the U.S. market.

Why it matters for patients

Semaglutide brand products, sold as Ozempic, Wegovy, and Rybelsus, remain protected by a web of patents that determine when lower-cost generic versions can be sold. This lawsuit is part of that legal landscape. A ruling against Novo on one patent does not mean a generic is available now. It means one legal barrier tied to one patent has been removed in this specific case, while other patents Novo asserted are still part of the same litigation, based on the information available.^[1]

For patients weighing the cost of brand-name GLP-1 drugs, cases like this help explain why cheaper generic semaglutide has not yet appeared in U.S. pharmacies, and why that timeline depends on court outcomes rather than on manufacturing readiness alone.

What happens next

The court's decision on the '003 patent was issued in July 2025.^[1] The sources here do not describe the status of the remaining four patents Novo asserted, or set any date for when the full case might resolve or when Mylan's generic semaglutide product might reach the market, so those details are not yet known.